|
| Status |
Public on Nov 28, 2017 |
| Title |
Alteration of treatment of the ALK inhibitor in ALK-amplified neuroblastoma |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Anaplastic Lymphoma Kinase (ALK) most frequently mutated in neuroblastoma (NB) and is atractive molecular target for therapy. However, efficacy of the ALK inhibitor against ALK-amplified NB is unclear.
To elucidate genetic alterations induced by treatment of the ALK inhibitor, we compared expression profile between ALK inhibitor-treated and DMSO-treated NB39nu cells using Agilent SurePrint G3 Human GE 8x60K V2 Microarray Kit
|
| |
|
| Overall design |
The ALK inhibitor or DMSO-treated NB39nu cells (parental and resistant), which harbor ALK amplification, were for RNA extraction and hybridization on Agilent microarrays.
|
| |
|
| Contributor(s) |
Miyazaki M, Hibiya Y, Enari M |
| Citation(s) |
29760954 |
| Submission date |
Nov 27, 2017 |
| Last update date |
May 22, 2019 |
| Contact name |
Makoto Miyazaki |
| Organization name |
National Cancer Research Center Institute
|
| Street address |
5-1-1, Tsukiji
|
| City |
chuo-ku, Tokyo |
| State/province |
State... |
| ZIP/Postal code |
104-0045 |
| Country |
Japan |
| |
|
| Platforms (1) |
| GPL17077 |
Agilent-039494 SurePrint G3 Human GE v2 8x60K Microarray 039381 (Probe Name version) |
|
| Samples (12)
|
|
| Relations |
| BioProject |
PRJNA419884 |
Less...
More...